Business Context and Reporting Period
This Form 8-K was filed by Virios Therapeutics, Inc. (trading symbol: VIRI) on February 26, 2024. The filing reports on corporate governance actions taken by the Board of Directors regarding employee and director compensation. Note: The request metadata referenced "Dogwood Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Virios Therapeutics, Inc.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on compensation adjustments and equity grants.
Material Changes
- Compensation Reductions: Effective March 1, 2024, the Board approved a 10% salary reduction for all employees, including executive officers. Additionally, a 10% reduction in cash compensation was approved for non-employee Board members.
- Equity Grants: To offset the cash compensation reductions, the Board granted stock options to executive officers and non-employee directors under the Amended and Restated 2020 Equity Incentive Plan.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking financial guidance, market outlook, or discussion of risks and contingencies beyond the immediate compensation changes. The stock options granted have an exercise price of $0.357 per share and will vest in full on February 26, 2025.
Option Grant Details:
| Name | Title | Number of Options |
|---|---|---|
| Greg Duncan | Chairman and CEO | 138,835 |
| R. Michael Gendreau | Chief Medical Officer | 88,085 |
| Ralph Grosswald | SVP of Operations | 62,568 |
| Angela Walsh | SVP of Finance, Secretary, Treasurer | 63,618 |
| Abel De La Rosa | Director | 3,959 |
| Richard Burch | Director | 2,917 |
| David Keefer | Director | 4,709 |
| Richard J. Whitley | Director | 4,000 |
| John C. Thomas | Director | 4,167 |
| William L. Pridgen | Director | 2,917 |
Investor Verification Checklist
- Verify the company name discrepancy between the request metadata (Dogwood Therapeutics) and the filing (Virios Therapeutics).
- Confirm the effective date of the 10% salary reduction (March 1, 2024) and its impact on future operating expenses.
- Review the vesting schedule of the new stock options (full vesting on February 26, 2025) to assess dilution risks.
- Check the current market price of VIRI stock relative to the $0.357 exercise price to determine if the options are in-the-money.